JP2020506715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506715A5 JP2020506715A5 JP2019543805A JP2019543805A JP2020506715A5 JP 2020506715 A5 JP2020506715 A5 JP 2020506715A5 JP 2019543805 A JP2019543805 A JP 2019543805A JP 2019543805 A JP2019543805 A JP 2019543805A JP 2020506715 A5 JP2020506715 A5 JP 2020506715A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- specific binding
- amino acid
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000009870 specific binding Effects 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 3
- 208000007656 osteochondritis dissecans Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010000234 Abortion spontaneous Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 201000001916 Hypochondriasis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000012981 Traumatic Stress disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 208000022266 body dysmorphic disease Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000015994 miscarriage Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000022530 polyphagia Diseases 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000000995 spontaneous abortion Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1702091.8A GB201702091D0 (en) | 2017-02-08 | 2017-02-08 | Specific binding molecules |
| GB1702091.8 | 2017-02-08 | ||
| PCT/EP2018/053232 WO2018146230A1 (en) | 2017-02-08 | 2018-02-08 | Anti human annexin a1 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506715A JP2020506715A (ja) | 2020-03-05 |
| JP2020506715A5 true JP2020506715A5 (OSRAM) | 2021-03-18 |
| JP7189142B2 JP7189142B2 (ja) | 2022-12-13 |
Family
ID=58462456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543805A Active JP7189142B2 (ja) | 2017-02-08 | 2018-02-08 | 抗ヒトアネキシンa1抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11041019B2 (OSRAM) |
| EP (1) | EP3579875B1 (OSRAM) |
| JP (1) | JP7189142B2 (OSRAM) |
| KR (1) | KR102687512B1 (OSRAM) |
| CN (1) | CN110475570B (OSRAM) |
| AU (1) | AU2018219595B2 (OSRAM) |
| BR (1) | BR112019016160A2 (OSRAM) |
| CA (1) | CA3052903C (OSRAM) |
| ES (1) | ES3009440T3 (OSRAM) |
| GB (1) | GB201702091D0 (OSRAM) |
| IL (1) | IL268506A (OSRAM) |
| MX (1) | MX2019009382A (OSRAM) |
| RU (1) | RU2019126888A (OSRAM) |
| WO (1) | WO2018146230A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013534914A (ja) | 2010-06-09 | 2013-09-09 | クイーン マリー アンド ウエストフィールド カレッジ、ユニバーシティ オブ ロンドン | アネキシン1抗体 |
| GB201121564D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Use of antibody |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| GB201813137D0 (en) * | 2018-08-10 | 2018-09-26 | Medannex Ltd | Cancer treatment with an antibody |
| CA3138550A1 (en) | 2019-04-30 | 2020-11-05 | Target Discovery Merger Sub II, LLC | Cancer associated antibody compositions and methods of use |
| CN114929276A (zh) * | 2019-11-20 | 2022-08-19 | 爱维盛新药股份有限公司 | 靶向人类cd47蛋白的单克隆抗体 |
| CN118465272B (zh) * | 2019-12-04 | 2025-08-19 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| WO2022178416A1 (en) * | 2021-02-22 | 2022-08-25 | Northwestern University | Anti-cd73 monoclonal antibodies |
| WO2023089150A1 (en) | 2021-11-18 | 2023-05-25 | Medannex Ltd. | Combination therapy for cancer |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8625941D0 (en) | 1986-10-30 | 1986-12-03 | Sandoz Ltd | Substituted alpha-amino acids |
| US5051364A (en) | 1989-02-16 | 1991-09-24 | The Salk Institute For Biological Studies | Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies |
| US5565338A (en) | 1990-06-04 | 1996-10-15 | La Jolla Institute For Allergy And Immunology | Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US20050118688A1 (en) | 2001-12-28 | 2005-06-02 | Hudson Freeze | Novel ligand involved in the transmigration of leukocytes across the endothelium and uses therefor |
| US8198020B2 (en) | 2003-08-22 | 2012-06-12 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| WO2005027965A1 (en) | 2003-09-24 | 2005-03-31 | Peter Krammer | Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
| CA2545166A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| EP1755646A2 (en) | 2004-06-02 | 2007-02-28 | Sidney Kimmel Cancer Center | Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| GB0822011D0 (en) | 2008-12-02 | 2009-01-07 | Queen Mary & Westfield College | Treatment |
| JP2013534914A (ja) * | 2010-06-09 | 2013-09-09 | クイーン マリー アンド ウエストフィールド カレッジ、ユニバーシティ オブ ロンドン | アネキシン1抗体 |
| CN102898527B (zh) | 2011-07-25 | 2016-12-21 | 三星电子株式会社 | 融合蛋白、药物组合物及预防或治疗癌症的方法 |
| GB201121561D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Transgenic animal |
| GB201121564D0 (en) * | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Use of antibody |
| KR20150029457A (ko) | 2013-09-10 | 2015-03-18 | 삼성전자주식회사 | 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도 |
-
2017
- 2017-02-08 GB GBGB1702091.8A patent/GB201702091D0/en not_active Ceased
-
2018
- 2018-02-08 CN CN201880022875.8A patent/CN110475570B/zh active Active
- 2018-02-08 US US16/484,286 patent/US11041019B2/en active Active
- 2018-02-08 WO PCT/EP2018/053232 patent/WO2018146230A1/en not_active Ceased
- 2018-02-08 AU AU2018219595A patent/AU2018219595B2/en active Active
- 2018-02-08 CA CA3052903A patent/CA3052903C/en active Active
- 2018-02-08 EP EP18707635.1A patent/EP3579875B1/en active Active
- 2018-02-08 JP JP2019543805A patent/JP7189142B2/ja active Active
- 2018-02-08 MX MX2019009382A patent/MX2019009382A/es unknown
- 2018-02-08 KR KR1020197026545A patent/KR102687512B1/ko active Active
- 2018-02-08 ES ES18707635T patent/ES3009440T3/es active Active
- 2018-02-08 RU RU2019126888A patent/RU2019126888A/ru unknown
- 2018-02-08 BR BR112019016160-0A patent/BR112019016160A2/pt unknown
-
2019
- 2019-08-05 IL IL268506A patent/IL268506A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506715A5 (OSRAM) | ||
| RU2019126888A (ru) | Антитело к человеческому аннексину а1 | |
| JP2020023523A5 (OSRAM) | ||
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| CN109311974A (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
| JP2010500876A5 (OSRAM) | ||
| Konwarh | Nanobodies: prospects of expanding the gamut of neutralizing antibodies against the novel coronavirus, SARS-CoV-2 | |
| JP2016524463A5 (OSRAM) | ||
| AU2016208161B2 (en) | IL-17A-binding polypeptides | |
| JP2017522903A5 (OSRAM) | ||
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| TW201326205A (zh) | 具有人類ox40專一性之抗體分子 | |
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| JP2014509510A5 (OSRAM) | ||
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2014508511A5 (OSRAM) | ||
| TW201233795A (en) | Chemokine receptor binding polypeptides | |
| JP2008527989A5 (OSRAM) | ||
| JP2007097598A5 (OSRAM) | ||
| JP2016520595A5 (OSRAM) | ||
| CN104684929A (zh) | 治疗血管疾病及其并发症 | |
| CN103497253A (zh) | 一种针对h2a.z变体的纳米抗体、其编码序列及应用 | |
| JP2013531991A5 (OSRAM) | ||
| CN109897107B (zh) | 纳米抗体及其制备方法 | |
| CN110483640B (zh) | 白介素-6r的人源化单克隆抗体、其编码基因及应用 |